Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1986 2
1990 2
1999 1
2002 1
2003 1
2005 1
2017 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Drugs for atopic dermatitis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96. Med Lett Drugs Ther. 2020. PMID: 32555122 No abstract available.
Diflorasone diacetate: vasoconstrictor activity and clinical efficacy of a new topical corticosteroid.
Bluefarb SM, Howard FM, Leibsohn E, Schlagel CA, Wexler L. Bluefarb SM, et al. J Int Med Res. 1976;4(6):454-61. doi: 10.1177/030006057600400613. J Int Med Res. 1976. PMID: 800385 Free article. Clinical Trial.
Diflorasone diacetate, a new topical corticosteroid, was generally more potent than three high potency reference standards (fluocinonide, beta-methasone 17-valerate and fluocinolone acetonide) when the compounds were dissolved in 95% alcohol and applied in vasoconstrictor
Diflorasone diacetate, a new topical corticosteroid, was generally more potent than three high potency reference standards (fluocinon
A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis.
Green L, Sadoff W. Green L, et al. J Cutan Med Surg. 2002 Mar-Apr;6(2):95-102. doi: 10.1007/s10227-001-0031-z. Epub 2002 Feb 13. J Cutan Med Surg. 2002. PMID: 11992180 Clinical Trial.
METHODS: A 12-week, multicenter, investigator-masked, randomized, parallel-group study was performed with more than 200 patients who were randomly assigned to regimens of tazarotene 0.1% gel alone, tazarotene plus a high-potency topical corticosteroid (fluocinonide 0.05% ointment …
METHODS: A 12-week, multicenter, investigator-masked, randomized, parallel-group study was performed with more than 200 patients who were ra …
AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
Bäumer W, Gorr G, Hoppmann J, Ehinger AM, Rundfeldt C, Kietzmann M. Bäumer W, et al. J Pharm Pharmacol. 2003 Aug;55(8):1107-14. doi: 10.1211/0022357021585. J Pharm Pharmacol. 2003. PMID: 12956900
Applied topically onto the ears before TDI challenge, AWD 12-281, cilomilast and diflorasone diacetate caused total inhibition of ear swelling 24 h after challenge, confirmed by a decrease of the pro-inflammatory cytokines interleukin-4, interleukin-6 and macrophage inhibi …
Applied topically onto the ears before TDI challenge, AWD 12-281, cilomilast and diflorasone diacetate caused total inhibition of ear …
[Topical treatment of glucocorticoid-sensitive dermatoses with diflorasone diacetate].
Rozman TA. Rozman TA. Z Hautkr. 1986 Mar 1;61(5):294, 297-304. Z Hautkr. 1986. PMID: 3962411 German.
Only 4% of the patients rated the tolerance of the ointment or cream as moderate or bad. None of the patients showed any systemic side-effects. The molecular structure of diflorasone-17,21-diacetate and the specific pharmaceutical properties of the ointment and crea …
Only 4% of the patients rated the tolerance of the ointment or cream as moderate or bad. None of the patients showed any systemic side-ef
Guidelines for using superpotent topical steroids.
Prawer SE, Katz HI. Prawer SE, et al. Am Fam Physician. 1990 May;41(5):1531-8. Am Fam Physician. 1990. PMID: 2333829
Superpotent topical steroids used to treat psoriasis and steroid-responsive dermatoses may produce local cutaneous side effects, including atrophy, steroid acne, perioral dermatitis, hypopigmentation, hypertrichosis and superinfections. Suppression of the hypothalamic-pitu …
Superpotent topical steroids used to treat psoriasis and steroid-responsive dermatoses may produce local cutaneous side effects, incl …
Ultrapotent topical corticosteroid treatment of childhood genital lichen sclerosus.
Garzon MC, Paller AS. Garzon MC, et al. Arch Dermatol. 1999 May;135(5):525-8. doi: 10.1001/archderm.135.5.525. Arch Dermatol. 1999. PMID: 10328191 Clinical Trial.
OBJECTIVE: To observe the clinical effects of short-term application of ultrapotent topical corticosteroid on symptomatic genital lesions of lichen sclerosus in pediatric patients. ...Frequency and severity of recurrences varied, but patients responded within a few days to …
OBJECTIVE: To observe the clinical effects of short-term application of ultrapotent topical corticosteroid on symptomatic genital les …
11 results